« Return to News | R&D Trends | Drug Sponsors

Novartis CEO unveils drug development strategy

Wednesday, May 4, 2011 12:43 PM

During a recent interview with Fortune, Novartis CEO Joe Jimenez explained the company's drug development strategy. He reported that Novartis isn’t targeting blockbuster indications but are more focused on pathways, as reported in Fierce Biotech.

By pursuing a particular disease pathway with a drug designed to treat a rare disease, Novartis improves its chances at gaining an approval from regulators, globally, says the CEO. Once it receives initial approval, it then expands on the treatment label by adding a more common disease that is affected by the same pathway.

"A good example of this is Ilaris, which is for a rare set of autoimmune diseases called cryopyrin-associated periodic syndrome," Jimenez told Fortune. "I think there are only 6,000 patients globally with this disease. But the mechanism, the pathway of this disease, is the same pathway that is prevalent in gout. And there are 3 million patients with acute gout. We have developed the drug in gout and we're awaiting FDA approval for this compound. This is a perfect example of how you would have multiple indications for the same drug and that's the way the drug would become--let's say, a blockbuster. Not that Ilaris will become a blockbuster but there will be multiple indications and multiple diseases through this fundamentally different approach."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.